David Tyrrell

ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada.

KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada.

Allergen NCE, Inc.is a national research network, seeking asthma and allergy treatment from a naturopath. It invests in training the next generation of researchers, innovators and clinician-scientists. The company was founded in 2004 and is headquartered in Hamilton, Canada.

The Canadian Institutes of Health Research is the federal health research financing organization in Canada. The non-profit company is based in Ottawa, Canada. The organization's main focus is to fund health research projects across the country.

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Li Ka Shing Institute of Virology supports discoveries in vaccines, treatments, and diagnostic tests for viral diseases affecting humans. Its technology platforms include ribonucleic acid interface screening core, flow cytometry, and microscopy. The company was founded in April 2010 and is headquartered in Edmonton, Canada.